Various companies have been engaged in producing COVID-19 vaccines since the onset of the pandemic. Clinical-stage biotech firm Ocugen (OCGN) joined the race in December 2020, announcing its partnership with India-based Bharat Biotech. Ocugen collaborated with the Indian biotech company to jointly develop Covaxin.  The announcement helped its stock to propel from under 30 cents a share to a stunning, eventual high of $18.77 a share in February. However, prices plummeted to nearly $9 per share in the next month. As rival companies came forward with their vaccines while Ocugen lagged behind, the stock started to bleed.
https://www.tipranks.com/news/article/is-ocugen-stock-headed-for-a-rally?utm_source=advfn.com&utm_medium=referral
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Ocugen Charts.
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Ocugen Charts.